Clinical trial finds novel therapy markedly reduces lipoprotein(a) levels in people with cardiovascular disease


Lipoprotein(a) is a special type of bad cholesterol that is believed to contribute to heart disease, but there are no approved pharmacological therapies to decrease its concentration in the bloodstream. Olpasiran is an investigational drug that reduces lipoprotein(a) concentration by degrading the RNA that codes for a protein that is an essential part of the molecule.

This wearable device could train your nervous system to deal with stress better

Previous article

Conservative state policies tied to higher mortality

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations